Brief: Jazz Pharmaceuticals To Acquire Chimerix
05/03/2025 12:47
March 5 (Reuters) - Chimerix CMRX.O: JAZZ PHARMACEUTICALS TO ACQUIRE CHIMERIX, FURTHER DIVERSIFYING ONCOLOGY PORTFOLIO CHIMERIX INC - DEAL VALUED AT $935 MILLION, OR $8.55 PER SHARE CHIMERIX INC - JAZZ TO FUND TRANSACTION THROUGH EXISTING CASH AND INVESTMENTS Source text: ID:nPn3n9k3Ga Further company coverage: CMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032